Get the Stockscreener App
39.92
1.84%
-0.75
After Hours:
39.75
-0.17
-0.43%
Sanofi Adr stock is traded at $39.92, with a volume of 4.32M.
It is down -1.84% in the last 24 hours and down -10.23% over the past month.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
See More
Previous Close:
$40.67
Open:
$39.58
24h Volume:
4.32M
Relative Volume:
1.49
Market Cap:
$95.65B
Revenue:
$49.41B
Net Income/Loss:
$5.59B
P/E Ratio:
16.72
EPS:
2.3875
Net Cash Flow:
$8.32B
1W Performance:
-2.89%
1M Performance:
-10.23%
6M Performance:
-16.64%
1Y Performance:
-20.38%
1-Day Range:
$39.50
$40.07
1-Week Range:
$39.50
$41.88
52-Week Range:
$39.50
$52.68
Sanofi Adr Stock (SNY) Company Profile
Name
Sanofi Adr
Sector
Industry
Phone
-
Address
-
Compare SNY vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNY
Sanofi Adr
|
39.92 | 98.51B | 49.41B | 5.59B | 8.32B | 2.3875 |
LLY
Lilly Eli Co
|
1,142.85 | 1.02T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.03 | 653.61B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
262.82 | 467.12B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
144.30 | 367.07B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
141.00 | 276.48B | 54.66B | 13.58B | 16.05B | 7.0171 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-26 | Downgrade | BNP Paribas Exane | Outperform → Neutral |
| Feb-12-26 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-27-26 | Initiated | Citigroup | Neutral |
| Jan-16-26 | Downgrade | UBS | Buy → Neutral |
| Jan-06-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-09-25 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-08-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-08-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-02-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-08-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Mar-21-25 | Initiated | Goldman | Neutral |
| Jan-30-25 | Upgrade | Deutsche Bank | Sell → Hold |
| Jul-26-24 | Reiterated | Argus | Buy |
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Dec-05-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-30-23 | Downgrade | Stifel | Buy → Hold |
| Sep-06-23 | Upgrade | Berenberg | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-28-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-27-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-13-22 | Resumed | Morgan Stanley | Overweight |
| Aug-12-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-09-22 | Downgrade | UBS | Buy → Neutral |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Sep-27-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jan-15-21 | Initiated | Deutsche Bank | Sell |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Mar-17-20 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-11-20 | Upgrade | Goldman | Neutral → Buy |
| Feb-11-20 | Initiated | SVB Leerink | Mkt Perform |
| Jan-06-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-20-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-03-19 | Initiated | Bernstein | Outperform |
| Aug-14-19 | Upgrade | UBS | Neutral → Buy |
| Dec-11-18 | Upgrade | Jefferies | Hold → Buy |
| Nov-01-18 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Sep-10-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Aug-10-18 | Upgrade | Citigroup | Neutral → Buy |
| Mar-23-18 | Upgrade | Liberum | Hold → Buy |
| Jan-23-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-06-17 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-01-17 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Nov-15-17 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-30-17 | Upgrade | HSBC Securities | Reduce → Hold |
View All
Sanofi Adr Stock (SNY) Latest News
Sanofi gains after expanding Regeneron partnership with $8 billion deal By Investing.com - Investing.com Australia
Sanofi (SNY) Stock Price, News, Quote & History - Yahoo! Finance Canada
SNW2 Stock Price and Chart — HAN:SNW2 - TradingView
Sanofi (SNY) stock price, news, quote and history - Yahoo Finance Singapore
ETFs Investing in Sanofi SA Sponsored ADR Stocks - TradingView
SNW2 Forecast — Price Target — Prediction for 2027 - TradingView
GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential? - Zacks Investment Research
10 New 5-Star Stocks This Week - Morningstar
Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59% - GlobeNewswire Inc.
The Best Healthcare Stocks to Buy - Morningstar
DPT Vaccine Market Size Report 2026: Projected to Reach 5,281.80 Million USD, Growing at a CAGR of 0.49% - note
Sanofi transfers 20 medicines to Cheplapharm partnership - grafa.com
Sanofi: Stronger Launches And A New R&D Reset Keep The Re-Rating Case Alive (NASDAQ:SNY) - Seeking Alpha
Sanofi stock edges higher as Deutsche Bank reiterates Buy rating - AD HOC NEWS
Sanofi partners with USA Pickleball to launch "Serve Up Protection" campaign to help protect older adults from COVID-19 with NUVAXOVID - Finviz
RBC Capital initiates Sanofi stock at Sector Perform on transition risks - Investing.com Canada
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - GlobeNewswire Inc.
Sanofi ADSADR Key Financial Ratios – Valuation, Profitability & More - Value Research
European ADRs Slipped In US Trading Late Thursday Morning - Finimize
Sanofi-ADR (NASDAQ:SNY): A Dividend Quality Candidate with Solid Profitability - ChartMill
Sanofi stock holds firm as workforce shake-up follows strong Q2 2026 - ad-hoc-news.de
Sanofi stock steadies after strong Q2 2026 and upgraded guidance - Ad-hoc-news.de
Sanofi stock steadies as upgraded 2026 guidance follows strong Q2 momentum - AD HOC NEWS
European ADRs Drift Lower In US Trading - Finimize
Sanofi stock climbs as MenQuadfi approval and cuts reshape the story - Ad-hoc-news.de
Sanofi stock edges higher as MenQuadfi approval and workforce reshaping define mid-August story - Ad-hoc-news.de
Sanofi's New Leadership Faces Looming Patent Cliff - Morningstar
6 Undervalued Stocks That Crushed Earnings - Morningstar
Resilient Sanofi stock edges higher as Q2 2026 growth and R&D reshuffle shape outlook - Ad-hoc-news.de
Sanofi stock holds steady as India unit boosts profit and secures tax refund - Ad-hoc-news.de
Trump considers order on autism and vaccines: which stocks are most exposed? - Investing.com
Nurix earns $10m milestone as Sanofi starts STAT6 degrader trial - Investing.com Nigeria
Key facts: Sanofi SA Sponsored ADR files H1 2026; halts three drugs - TradingView
What's behind Sanofi's latest 5.4% stock pullback? - tradersunion.com
European ADRs Jump In US Trading As Banks Lead - Finimize
Sanofi Adr Stock (SNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):